Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
76 Epilepsy Trials
Power is an online platform that helps thousands of Epilepsy patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Cannabidiol for Chronic Liver Injury Prevention
Wichita, KansasThis study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:1+
Sex:All
154 Participants Needed
CVL-865 for Seizures
Oklahoma City, OklahomaThe purpose of this study is to assess the long-term safety and tolerability of CVL-865 as adjunctive therapy in participants with focal onset seizures.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
105 Participants Needed
Responsive Neurostimulation for Generalized Epilepsy
Kansas City, KansasTo demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.
Stay on current meds
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12+
Sex:All
100 Participants Needed
DBS Therapy for Epilepsy
Kansas City, KansasThe purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Generalized Epilepsy, Psychogenic Seizures, Others
Must Be Taking:Antiepileptic Drugs
140 Participants Needed
XEN1101 for Epilepsy
Kansas City, KansasThis trial will test the safety and effectiveness of taking a 25 mg pill of XEN1101 in patients with specific types of seizures. The goal is to see if it can help control their seizures by affecting brain activity. Participants must have completed earlier related studies.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:12+
Sex:All
880 Participants Needed
XEN1101 for Epilepsy
Kansas City, KansasThis trial tests XEN1101, a new medication, in adults with focal epilepsy who still have seizures despite taking other anti-epileptic drugs. The goal is to see if XEN1101 can better control their seizures by working with their current medications.
Stay on current meds
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
325 Participants Needed
Prone Positioning Device for Neurosurgery
Kansas City, KansasThe goal of this study is to learn if the prototype adjustable prone positioning frame is a feasible design for use during neurosurgical procedures which utilize intraoperative magnetic resonance imaging (iMRI). The main questions it aims to answer are:
* Is the prototype prone positioning device design feasible for use during neurosurgical procedures which utilize intraoperative MRI?
* Does use of the prototype device place the patient at increased risk of complications compared to the standard positioning pads? Researchers will place patients in the prone position on the prototype device during neurosurgical procedures that utilize intraoperative MRI and observe for any problems with the positioning device or complications attributable to the positioning device.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
5 Participants Needed
Cenobamate for Focal Seizures
Kansas City, KansasCenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagnosed or recurrent POS/focal onset epilepsy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 74
Sex:All
Key Eligibility Criteria
Disqualifiers:Lennox-Gastaut, Status Epilepticus, Psychogenic Seizures, Others
Must Not Be Taking:Strong CYP3A Inducers
90 Participants Needed
RAP-219 for Partial Seizures
Kansas City, KansasThis is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Generalized Seizures, Status Epilepticus, Epilepsy Surgery, Others
20 Participants Needed
XEN1101 for Seizures
Kansas City, KansasThis trial tests XEN1101, a medication added to current treatments, in people with generalized epilepsy experiencing PGTCS who are already on 1-3 anti-seizure medications. The goal is to see if taking XEN1101 with an evening meal can help reduce seizure frequency.
Stay on current meds
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12+
Sex:All
Key Eligibility Criteria
Disqualifiers:Focal-onset Seizures, Schizophrenia, Bipolar, Others
Must Be Taking:Antiseizure Medications
160 Participants Needed
XEN1101 for Seizures
Kansas City, KansasThe X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Stay on current meds
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Non-epileptic Seizures, Generalized Seizures, Others
Must Be Taking:Antiseizure Medications
360 Participants Needed
Ganaxolone for TSC-Related Epilepsy
Kansas City, MissouriThis is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated in either Study 1042-TSC-3001 or Study 1042-TSC-2001
Stay on current meds
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:1 - 65
Sex:All
132 Participants Needed
BHV-7000 for Epilepsy
Lincoln, NebraskaThe purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Status Epilepticus, Repetitive Seizures, Others
Must Be Taking:Antiseizure Medications
242 Participants Needed
BHV-7000 for Epilepsy
Lincoln, NebraskaThe purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Status Epilepticus, Cluster Seizures, Others
Must Be Taking:Anti-seizure Medications
390 Participants Needed
BHV-7000 for Epilepsy
Lincoln, NebraskaA study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:18 - 75
Sex:All
660 Participants Needed
BHV-7000 for Epilepsy
Rogers, ArkansasThe purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Status Epilepticus, Cluster Seizures, Others
Must Be Taking:Anti-seizure Medications
390 Participants Needed
EPX-100 for Dravet Syndrome
Omaha, NebraskaThe purpose of this study is to evaluate the safety and efficacy of EPX-100 as adjunctive therapy in participants with Dravet syndrome.
Stay on current meds
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:2 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Suicidal Thoughts, Cardiac Disease, Others
Must Be Taking:Aeds
100 Participants Needed
NRTX-1001 Neural Cell Therapy for Epilepsy
Omaha, NebraskaThis trial tests if injecting special brain cells into the brain can help patients with hard-to-treat epilepsy. The new cells release a calming chemical to reduce seizures. Patients will also take medicines to prevent their bodies from rejecting the new cells.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Neurologic Disease, Immunodeficiency, Psychiatric Disorders, Others
Must Be Taking:ASDs
58 Participants Needed
Cenobamate for Epilepsy
Columbia, MissouriThis trial aims to ensure the safety of cenobamate, a seizure control medication, for patients who have already participated in a previous study. Cenobamate helps by calming overactive brain signals that cause seizures. Cenobamate is a new medication approved by the FDA in 2019 for the treatment of focal-onset seizures in adults.
Stay on current meds
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:12+
Sex:All
145 Participants Needed
Cenobamate for Epilepsy
Columbia, MissouriPrimary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:2 - 18
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Pseudo-seizures, Psychiatric Disorders, Others
Must Be Taking:Antiepileptic Drugs
140 Participants Needed
Cenobamate for Seizures
Columbia, MissouriThis trial tests cenobamate, a new medication for controlling seizures, in adults and adolescents with a specific type of epilepsy. The medication is taken regularly to stabilize brain activity and reduce seizures. Cenobamate has shown high effectiveness in previous studies.
Stay on current meds
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12+
Sex:All
169 Participants Needed
Age-Based Seizure Protocol for Pediatric Seizures
Dallas, TexasThe Pediatric Dose Optimization for Seizures in Emergency Medical Services (PediDOSE) study is designed to improve how paramedics treat seizures in children on ambulances. Seizures are one of the most common reasons why people call an ambulance for a child, and paramedics typically administer midazolam to stop the seizure. One-third of children with active seizures on ambulances arrive at emergency departments still seizing. Prior research suggests that seizures on ambulances continue due to under-dosing and delayed delivery of medication. Under-dosing happens when calculation errors occur, and delayed medication delivery occurs due to the time required for dose calculation and placement of an intravenous line to give the medication. Seizures stop quickly when standardized medication doses are given as a muscular injection or a nasal spray. This research has primarily been done in adults, and evidence is needed to determine if this is effective and safe in children.
PediDOSE optimizes how paramedics choose the midazolam dose by eliminating calculations and making the dose age-based. This study involves changing the seizure treatment protocols for ambulance services in 20 different cities, in a staggered and randomly-assigned manner.
One aim of PediDOSE is to determine if using age to select one of four standardized doses of midazolam and giving it as a muscular injection or nasal spray is more effective than the current calculation-based method, as measured by the number of children arriving at emergency departments still seizing. The investigators believe that a standardized seizure protocol with age-based doses is more effective than current practice.
Another aim of PediDOSE is to determine if a standardized seizure protocol with age-based doses is just as safe as current practice, since either ongoing seizures or receiving too much midazolam can interfere with breathing. The investigators believe that a standardized seizure protocol with age-based doses is just as safe as current practice, since the seizures may stop faster and these doses are safely used in children in other healthcare settings.
If this study demonstrates that standardized, age-based midazolam dosing is equally safe and more effective in comparison to current practice, the potential impact of this study is a shift in the treatment of pediatric seizures that can be easily implemented in ambulance services across the United States and in other parts of the world.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:6 - 13
Sex:All
Key Eligibility Criteria
Disqualifiers:Benzodiazepine Allergy, Pregnancy, Growth Restriction
6000 Participants Needed
Fenfluramine for CDKL5 Deficiency Disorder
Dallas, TexasThis trial tests ZX008, a medication added to current treatments, in children and adults with CDD who have uncontrolled seizures. The goal is to see if ZX008 can help better control their seizures.
Stay on current meds
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:1 - 35
Sex:All
87 Participants Needed
Fenfluramine for Dravet and Lennox-Gastaut Syndromes
Dallas, TexasThis is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:2+
Sex:All
412 Participants Needed
Scopolamine for Memory Loss
Dallas, TexasThe goal of this study is to learn about the effects of scopolamine (an anticholinergic drug) on areas of the brain involved in memory, and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.
The main questions it aims to answer are 1) whether scopolamine changes memory activity solely at encoding (the time when the person perceives and determines to remember an item or event) as has previously been found, or if it also can selectively impact retrieval (when the item or event which has been processed is recalled or remembered), and 2) what the nature of the brain activity changes is.
Participants will complete two treatment arms. One of these will be with the drug, and the other will be with a saline solution, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal and/or spatial task each of the two days. An anesthesiologist will administer either the drug or the saline at a critical point which addresses both of the research questions.
Researchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and at what time point during memory formation.
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Renal Insufficiency, Cardiac Syndrome, Others
Must Not Be Taking:Cannabinoids, Cocaine, Amphetamines, Barbiturates
60 Participants Needed
Brain Stimulation for Memory Impairments in Epilepsy
Dallas, TexasThe purpose of this research is to understand biomarkers of human memory through correlational analyses and to use focal electrical stimulation as a causal manipulation to understand how biomarkers of memory relate to other brain states and behavioral measures.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 65
Sex:All
800 Participants Needed
Fenfluramine for Dravet Syndrome
Dallas, TexasThe primary purpose of this study is evaluate the safety and tolerability of fenfluramine hydrochloride (HCl) 0.2 to 0.8 mg/kg/day in infants 1 year to less than 2 years of age with Dravet syndrome.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:1 - 23
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Glaucoma, Others
Must Be Taking:Antiseizure Medications
20 Participants Needed
Soticlestat for Dravet Syndrome
Fort Worth, TexasThis trial tests soticlestat to reduce seizures in children and adults with Dravet Syndrome or Lennox-Gastaut Syndrome. Soticlestat helps by targeting brain pathways involved in seizure activity. The study will evaluate its safety, effectiveness, and tolerance over time.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:2 - 56
Sex:All
Key Eligibility Criteria
Disqualifiers:Unstable Neurologic, Psychiatric, Cardiovascular, Others
Must Be Taking:Anti-seizure Therapy
400 Participants Needed
NBI-921352 for Epilepsy
Fort Worth, TexasThe objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
Stay on current meds
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:2 - 21
Sex:All
52 Participants Needed
Soticlestat for Rare Epilepsies
Fort Worth, TexasThe main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment.
Participants will receive soticlestat twice a day. Participants will visit the study clinic every 2-6 months throughout the study.
Study treatments may continue as long as the participant is receiving benefit from it.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:2 - 65
Sex:All
156 Participants Needed
Page 1 of 3+
Frequently Asked Questions
How much do Epilepsy clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Epilepsy clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Epilepsy trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Epilepsy is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Epilepsy medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Epilepsy clinical trials ?
Most recently, we added Brain Interchange System for Epilepsy, Vagal Nerve Stimulation for Gastric Motor Functions and NPT 2042 for Epilepsy to the Power online platform.